

Der Allgemeinarzt

Treating Osteoarthritis of the Knee:

A Modern Homeopathic Medication Works as well as COX 2 Inhibitors

Heinz Birnesser, Peter Klein, Michael Weiser

Reprint

● 2003;25(4)

■ pp. 261-4

▲ *Kirchheim-Verlag
Mainz*

Treating Osteoarthritis of the Knee:

A Modern Homeopathic Medication Works as well as COX 2 Inhibitors

Heinz Birnesser, Peter Klein, Michael Weiser

Introduction

Relieving pain and reducing inflammation are the cornerstones of pharmaceutical therapy for osteoarthritis of the knee. Depending on the patient's symptoms, treatment may be either systemic or topical and may include peripherally active analgesics, anti-inflammatories such as COX 1 or COX 2 inhibitors, topical steroids, hyaluronic acid, and therapeutic injections of local anesthetics.¹ More and more physicians, however, are prescribing alternative therapeutic measures.

In homeopathy, for example, potentized extracts of *Rhus toxicodendron*, *Solanum dulcamara*, and *Sanguinaria canadensis* are used to relieve the pain and inflammation of rheumatic conditions. These three ingredients are combined with *Arnica montana* and sulfur in the homeopathic medication Zeel® comp. N (tablets).

A previous controlled, double-blind clinical study proved that the clinical efficacy of this combination medication is equivalent to that of COX 1 inhibitors in treating mild to moderate osteoarthritis of the knee.^{2,3} The purpose of the present study is to compare the efficacy of Zeel® comp. N and COX 2 inhibitors.

Methods

Design of the study

The investigation was conducted as an open, prospective, multicenter, reference-controlled cohort study. To minimize the possibility of treatment bias, the 127 participating physicians (primarily general practitioners) were separated into two groups, one of which prescribed only Zeel® comp. N and the other only COX 2 inhibitors.

Patients

All 592 patients admitted to the study had Stage I or Stage II osteoarthritis of the knee as defined by Richter.⁴ Exclusion criteria included Stage III or IV osteoarthritis and concomitant pharmaceutical treatment for osteoarthritis with prescription drugs other than those prescribed for purposes of the study. Nonpharmaceutical therapies and short-term use of OTC pain relievers were permitted.

Target criteria

In each case, efficacy of treatment was evaluated by both the physician and the patient. Upon commencement of therapy and over the course of the study, the physicians assessed the degree of severity of four cardinal symptoms (initial pain with movement, pain continuing during movement or weight-bearing exercise, pain when fatigued, and joint stiffness/tension) on a four-point scale (no symptoms, mild, moderate, severe). Physicians also documented the point in time of onset of symptomatic im-

provement and rated the overall results of therapy on a five-point scale (very good, good, fair, no success, worse) on conclusion of treatment. Patients evaluated their progress during the study with the help of a validated German version of the WOMAC Osteoarthritis Index.⁵

Individual test parameters were documented for each patient at an entry examination, an interim examination after approximately four weeks of treatment, and a final examination after at least six but no more than ten weeks.

Test substances

The test medication was Zeel® comp. N (tablets); the reference substances were the COX 2 inhibitors Celebrex® (active ingredient celecoxib, 100 or 200 mg hard capsules) and Vioxx® (active ingredient rofecoxib, 12.5 or 25 mg tablets).⁶⁻¹⁰


Statistics

To compensate for treatment differences among covariates, Rosenbaum's method of logistic regression was applied.^{11, 12} This statistical procedure permits calculation of propensity scores, which were then matched to reduce distortion in comparing the nonrandomized treatment groups.^{11, 13} Adjusted differences in the size of effects were calculated with 95 percent confidence intervals. Confidence intervals were calculated through analysis of covariance. The purpose of the statistical analysis was to demonstrate that treatment with

Zeel® comp. N is non-inferior (not less effective) than treatment with the above-mentioned COX 2 inhibitors at an equivalence limit of 10 percent (one-sided probability of error = 0.025).

Ethics

The study was conducted in accordance with the German recommendations (12 November 1998) for planning, implementing, and evaluating drug monitoring studies.¹⁴



Radiological findings in Stage II osteoarthritis

Findings

Treatment

Of the patients receiving Zeel® comp. N (n = 323), 44 percent took one tablet three times a day, while 24 percent took one tablet four times a day and 27 percent took one tablet five times a day. For 88 percent of the patients in the test group, the dosage remained unchanged throughout the treatment period. In the reference group (n = 269), 109 patients were treated with celecoxib and 160 with rofecoxib. Participating physicians were left free to decide which COX 2 inhibitor to prescribe for each patient in this group.

Severity of symptoms

Upon commencement of the study, all four cardinal symptoms as assessed by the physicians (initial pain with movement, pain continuing during movement or weight-bearing exercise, pain when fatigued, and joint stiffness or sensation of tension) were moderately severe in both treatment groups, and the groups were comparable in terms of severity of symptoms (p > 0.05). After four weeks, significant improvement in all symptoms was observed under both treatment regimens. Improvement was somewhat more pronounced in the group receiving COX 2 inhibitors due to the more rapid onset of efficacy of this type of medication. After six weeks of treatment, scores indicated that the homeopathic medication and the COX 2 inhibitors were equally effective.

The WOMAC Osteoarthritis Index

Upon commencement of therapy, both groups of patients reported pain in the mid-range of the Visual Analog Scale. As with the cardinal symptoms listed above, after four weeks of treatment the WOMAC Osteoarthritis Index also revealed greater reductions in pain in the group taking COX 2 inhibitors. By the end of the treatment period, however, the difference lay inside the confidence interval, i.e., the efficacy of therapy was equivalent in the two groups.

Onset of efficacy

As expected, improvement in cardinal symptoms occurred significantly earlier in the COX 2 inhibitor group. 48 percent of these patients (in comparison to 20 percent in the test group) reported improvement within two weeks. This difference was eliminated, however, within the next two to three weeks.

Results of therapy

Overall ratings of therapeutic efficacy and patient compliance were generally comparable in the two treatment groups. Patient compliance was

rated "good" or "very good" for 98 percent of the test group and 97 percent of the COX 2 group (p = 0.129). 79 and 86 percent, respectively, rated the overall results of their treatment as "good" or "very good" (p = 0.160). 63 percent of the test group and 59 percent of the reference group continued treatment after the end of the study.

Tolerability

The test medication scored significantly higher with regard to tolerability (p < 0.0001) than the COX 2 inhibitors. 90 percent of the patients taking the homeopathic medication tolerated it "very well" in comparison to only 74 percent taking the reference medications.

Adverse drug events

Among the patients taking COX 2 inhibitors, three incidents of undesired effects were reported: edema, diarrhea/vomiting/dizziness, and (in the third case) unspecified gastric complaints. The physicians reported that COX 2 inhibitor therapy was "probably" related to the gastric complaints and "possibly" related to the edema but did not comment on the possibility of a connection between therapy and the case of diarrhea/vomiting/dizziness. No adverse events were reported in the Zeel® comp. N group.

Discussion

This cohort study was conducted according to criteria established by Benson and Concato.^{21, 22} After a maximum treatment period of ten weeks, Zeel® comp. N achieved clinical efficacy comparable to that of COX 2 inhibitors as evidenced both by the WOMAC Osteoarthritis Index and by improvement in cardinal symptoms. Furthermore, there were no statistically significant differences between the test and reference groups in ratings of patient compliance and overall success of the therapies. On the other hand, pa-




Fig.: Change in scores on the WOMAC Osteoarthritis Index and its subscales over the course of the study. (EE = entry examination, IE = interim examination [after 30-32 days on average], FE = final examination [after 60-64 days on average])

tients gave the homeopathic medication significantly higher scores for tolerability than the COX 2 inhibitors. All three adverse drug events occurred in the COX 2 inhibitor group, and in two of the three cases the physicians reported possible/probable causative connections.

The purpose of pharmaceutical therapy for osteoarthritis is to relieve pain, improve mobility, and prevent progression of inflammation. To achieve these ends, analgesic and anti-inflammatory medications such as NSAIDs, unselective COX 1 inhibitors, and selective COX 2 inhibitors are commonly prescribed.¹ There are distinct differences, however, in the pharmacological activity of these types of medications. Traditional NSAIDs inhibit both COX 1 and COX 2; their therapeutic effects are due to inhibition of inducible COX 2^{15, 16} while their gastrointestinal, renal, and cardiovascular side effects are based on inhibition of constitutive COX 1 activity.¹⁵⁻¹⁸ With fewer side effects of this sort, selective COX 2 inhibitors are considered an advance over COX 1 inhibitors in the treatment of painful rheumatic symptoms.^{15-17, 20} (The incidence of cardiovascular and renal disease increases with advancing age and approximately 40 percent of arthritis

patients are treated concurrently for hypertension and/or arteriosclerosis).¹⁷⁻¹⁹ But although COX 2 inhibitors cause fewer side effects, adverse events (primarily cardiovascular) are still known to occur.¹⁷

Because the COX 2 isozyme plays an important role in healing processes (including ulcer healing) and in maintaining homeostasis (with regard to blood pressure and vasoregulation, kidney function, CNS functions, and bone metabolism), inhibiting COX 2 is not completely unproblematic.¹⁷ A more physiologically sound therapeutic approach is to reduce the concentration of proteolytic enzymes (serine proteinases and metalloproteinases) that support inflammation in the extracellular matrix. Suppressing these enzymes also prevents COX 2 overexpression. This is where Zeel® comp. N proves superior: in vitro studies have demonstrated that its ingredients effectively inhibit both serine proteinases and metalloproteinases.^{23, 24}

Conclusions

This study proves that Zeel® comp. N is as effective as the COX 2 inhibitors celecoxib and rofecoxib and is significantly better tolerated. Therefore, this homeopathic combination medica-

tion offers a real alternative to allopathic drugs in treating mild to moderate osteoarthritis of the knee. Due to its lower cost and the fact that it virtually eliminates the need for secondary medication to control adverse effects, Zeel® comp. N should also reduce the cost of long-term arthritis management.

*For the authors:
Dr. Michael Weiser
Institute for Antihomotoxic
Medicine and Ground Regulation
Research
Bahnackerstr. 16
76532 Baden-Baden, Germany*

References

1. *Dt. Ges. f. Orthopädie und Traumatologie + Berufsverb. d. Ärzte f. Orthopädie (eds.). Leitlinien der Orthopädie.* Köln: Dt. Ärzte-Verlag 1999;41ff.
2. Strösser W, Weiser M. Patienten mit Gonarthrose gewinnen ihre Mobilität zurück. *Biol Med* 2000;29(6):295-9
3. Marrona U, Weiser M, Klein P. Orale Behandlung der Gonarthrose mit Zeel® comp. *Orthopädische Praxis* 2000;(5):285-91
4. Richter M. *Arthrose.* München: PVG Pharmazeutische Verlagsgesellschaft mbH 1983;100-7
5. Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Dick W, Theiler R. Evaluation of a German version of WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. *Z Rheumatol* 1996;55(1):40-9
6. Geba GP, Weaver AL, Polis AB, et al. Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in osteoarthritis of the knee. *JAMA* 2002;287(1):64-70
7. Fuchs B. Celecoxib und Rofecoxib, zwei COX-2-selektive Entzündungshemmer. *Pharm Ztg* 2001;146(15):1229-38
8. Hinz B, Brune K. Cyclooxygenase-2 – 10 years later. *J Pharmacol Exp Ther* 2002;300(2):367-75
9. *Fachinformation Celebrex.* Date: October 2002
10. *Fachinformation Vioxx.* Date: January 2001
11. Rosenbaum PR, Rubin D. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;70(1):41-55
12. Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med* 1997;127(8 Pt 2):757-63
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med* 1998;17(19):2265-81
14. *Bundesanzeiger* No. 299 of December 4, 1998: Empfehlungen zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen vom 12. November 1998
15. Brune K, Kalden J, Zacher J et al. Selektive Inhibitoren der Zyklooxygenase 2. Evolution oder Revolution? *Dtsch Ärztebl* 2000;97:A1818-25
16. Crofford LJ, Lipsky PE, Brooks P et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. *Arthritis Rheum* 2000;43:4-13
17. John S, Schmieder RE. Beeinflussen COX-2-Inhibitoren das kardiovaskuläre Risiko? *DMW* 2002;127:156-9
18. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs effect blood pressure? *Ann Intern Med* 1994;121:289-300
19. Spence JD. The arthritic patient with hypertension: selection of an NSAID. *Scand J Rheumatol Suppl* 1986;62:36-40
20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA* 2001;286(8):954-9
21. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. *N Engl J Med* 2000;342(25):1878-86
22. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 2000;342(25):1887-92
23. Heine H. *Lehrbuch der biologischen Medizin.* 2nd ed. Stuttgart: Hippokrates Verlag 1997;39-41
24. Stancikova M. Hemmung der Leukozytelenelastase-Aktivität in vitro mit Zeel T, Zeel comp. und ihren verschiedenen Bestandteilen. *Biol Med* 1999;28(2):83-4